Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Thomas Hong - Manager-Investor Communications Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Charlie Young - Bank of America Yi Chen - H.C. Wainwright Operator Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) (State or other jurisdiction of incorporation or organiza ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Thomas Hong – Manager-Investor Communications Jacque Shea – President and Chief Executive Officer Michael Sumner – Chief Medical Officer Peter Kies – Chief Financial Officer Conference Call Participants Hartaj Singh – Oppenheimer & Company Operator Good day and welcome to the Inovio Third Quarter 2022 Results Conference Call. [Operator instructions] Please note that this event is being ...

Corporate Presentation November 2022 :INO Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements,"" within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Jacqueline Shea - President and CEO Conference Call Participants Brooke Katsof - H.C. Wainwright Brooke Katsof Good morning, everyone and thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference from September 12 to the 14, 2022. My name is Brooke Katsof and I'm an H.C. Wainwright analyst. While we are hybrid this year, we're c ...

Financial Data and Key Metrics Changes - The company finished Q2 2022 with $348.1 million in cash, cash equivalents, and short-term investments, down from $360.4 million as of March 31, 2022 [23] - Total revenue for Q2 2022 was $784,000, compared to $273,000 for the same period in 2021, reflecting an increase due to the delivery of proprietary smart devices related to a contract with the U.S. Department of Defense [24] - Total operating expenses were $104.9 million for Q2 2022, up from $83.5 million in Q2 2021, with a net loss of $108.5 million or $0.46 per share, compared to a net loss of $82.1 million or $0.39 per share in the prior year [25][27] Business Line Data and Key Metrics Changes - Research and development expenses decreased to $56.5 million in Q2 2022 from $70.8 million in Q2 2021, primarily due to lower expenses related to manufacturing equipment acquisition [26] - General and administrative expenses increased significantly to $48.5 million in Q2 2022 from $12.7 million in Q2 2021, largely due to a $26 million increase in legal expenses [27] Market Data and Key Metrics Changes - The company is focusing on advancing its COVID-19 vaccine candidate INO-4800 and HPV-related product candidates, particularly INO-3107, which are seen as having the most potential for reaching the market soon [40][41] Company Strategy and Development Direction - The company is restructuring to align with product development goals, including an 18% reduction in full-time workforce and an 86% reduction in contractors, aiming for a 30% reduction in operating expenses over the next 18 months [8] - The strategic focus remains on advancing product candidates that are closer to market, particularly in the areas of HPV and COVID-19 [40] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of INO-4800 as a heterologous booster, highlighting its ability to elicit immune responses against multiple variants of concern [35][41] - The company is awaiting data from the REVEAL 2 trial for VGX-3100, which will inform future steps for the program [44][58] Other Important Information - The company anticipates a cash burn of approximately $73 million for Q3 2022, with projections extending the cash runway into Q3 2024 [30] - The proposed settlement of a class action lawsuit is expected to involve a $30 million cash payment and $14 million in common stock, pending court approval [28][29] Q&A Session Summary Question: Can you talk about how your COVID strategy has evolved? - The company continues to monitor market factors and believes that heterologous boosters may provide broader protection against variants, positioning INO-4800 as a significant candidate [35][36] Question: What are some surprises and challenges you've encountered? - The focus has been on realigning resources to advance product candidates with the most market potential, particularly in HPV and COVID-19 [40] Question: What kind of data are you looking for in the REVEAL 2 trial? - The company hopes to meet predetermined efficacy and safety endpoints, which will guide the next steps for VGX-3100 [44] Question: What are the next steps for the GBM program? - The company is encouraged by the survival data and is in discussions with partners about future steps [46] Question: What are the regulatory requirements for INO-4800? - Discussions with regulators are ongoing, and specific country names cannot be disclosed at this time [50] Question: Can you provide an update on CELLECTRA device utilization? - The company is using multiple devices for different clinical trials, including the 5PSP and CELLECTRA devices [51] Question: What is the market sizing for MERS, Lassa fever, and Ebola? - The company plans to provide updates on these clinical programs later in the year, emphasizing their global implications [52] Question: Is INO-3107 on track to report results by the end of the year? - Yes, the company anticipates sharing results from the Phase I/II trial in the second half of the year [54]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q COMMISSION FILE NO. 001-14888 https://files.reportify.cc/media/p INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 660 W. GERMANTOWN PIKE, SUITE 110 PLYMOUTH MEETING, PA 19462 (Address of principal executive offices) REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (267) 4 ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Jefferies 2022 Global Healthcare Conference June 8, 2022 1:00 PM ET Company Participants Jacqui Shea - CEO Jeffrey Skolnik - CMO Conference Call Participants Roger Song - Jefferies Roger Song Good afternoon, everyone. Welcome to Jefferies Global Healthcare Conference day one afternoon. My name is Roger Song, one of the senior analysts on the biotech research team in the US. Our next presenting company from -- is Inovio and the presenter is the CEO, Jacqui and CMO, J ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of ...